insulin vs glp-1 vs. GLP-1 + GIP: What's the Difference for your Metabolism? The Surprising Truth About Nutrition
Description
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, at higher doses (marketed as Wegovy), for weight management in adults with obesity or overweight with weight-related comorbidities
Analog 52 was identified as the most active analog based on the PPRE relative activities
Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden
Manufacturers could also benefit from monitoring restrictions and identifying alignment to GLP-1 clinical value story, while keeping eyes open for partnership opportunities
Roche entered this race in 2024 when it acquired Carmot Therapeutics for $2.7 billion, gaining CT-388 (RO7690479), a dual GLP-1R/GIPR agonist with a distinct receptor profile
Daniel Ciccarone, an addiction-medicine professor at UCSF
